EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinie

MASLD: Established Knowledge and Emerging Directions – Guideline Updates

Elke Roeb, Andreas Geier

Zeitschrift für Gastroenterologie · 01.09.2026 · 64 (09) · 1239-1249

DOI: 10.1055/a-2894-7628 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2026. Verfasst von Elke Roeb und 1 weiteren Autor:innen. Beteiligte Einrichtung: Justus Liebig University Giessen, Gastroenterology, Germany, Giessen. Hauptthemen laut MEDLINE: Practice Guidelines as Topic, Fatty Liver. Die Arbeit nennt 86 Literaturangaben. Gefördert von: German Research Foundation, DFG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major global health challenge, largely driven by the increasing prevalence of obesity and type 2 diabetes mellitus. The disease spectrum ranges from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH) with progressive fibrosis. Advanced fibrosis substantially increases the risk of cirrhosis, hepatocellular carcinoma, and cardiovascular complications, thereby contributing significantly to morbidity and mortality.Although lifestyle modification remains the cornerstone of therapy, pharmacological treatment is gaining importance in patients with progressive disease or high-risk profiles. Advances in the understanding of MASLD pathophysiology have enabled the development of targeted therapies addressing hepatic lipid accumulation, insulin resistance, inflammation, and fibrogenesis. Promising clinical data have been reported for resmetirom, semaglutide, tirzepatide, survodutide, lanifibranor, and fibroblast growth factor-21 analogues including efruxifermin, pegozafermin, and efimosfermin.This review summarises current and emerging diagnostic and therapeutic strategies and provides practical guidance for clinical management. In addition, a structured treatment algorithm for non-cirrhotic MASLD (F0–F3), restricted to therapies currently available in Europe and stratified according to diabetes status and fibrosis stage, is proposed as an evidence-based tool for routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Practice Guidelines as TopicFatty LiverHumansEvidence-Based MedicineSemaglutide

Substanzen

Semaglutide

Autor:innen und Institutionen

  • Justus Liebig University Giessen, Gastroenterology, Germany, Giessen.
  • University of Würzburg, Internal Medicine, Germany, Würzburg.

Förderung

  • German Research Foundation, DFG

Zitieren

APA

Roeb, E., & Geier, A. (2026). MASLD: Established Knowledge and Emerging Directions – Guideline Updates. Zeitschrift für Gastroenterologie, 64(09), 1239-1249. https://doi.org/10.1055/a-2894-7628

Vancouver

Roeb E, Geier A. MASLD: Established Knowledge and Emerging Directions – Guideline Updates. Zeitschrift für Gastroenterologie. 2026;64(09):1239-1249. doi:10.1055/a-2894-7628

BibTeX
@article{Roeb2026,
  author = {Roeb, Elke and Geier, Andreas},
  title = {MASLD: Established Knowledge and Emerging Directions – Guideline Updates},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2026},
  volume = {64},
  number = {09},
  pages = {1239--1249},
  doi = {10.1055/a-2894-7628}
}
Kostenlos starten →